Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

artFibro

Financiado

Artifying fibroblasts: Perturbation modelling in the lung tumor phase space to r...

Artifying fibroblasts: Perturbation modelling in the lung tumor phase space to rewire fibroblasts for immunotherapy. Lung cancer is the leading cause of cancer death. Immunotherapy improved survival rates, but efficacy is limited to selected patients. We recently discovered universal antigen presenting fibroblasts (apFibros) across human and mur... ver más

31/03/2028

BIOMEDICALSCIENCES...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-27

ERC-2022-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

BIOMEDICALSCIENCES RESEARCH...

2.00M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

RARITY RAtional design of canceR ImmunoTherapY one size does not f... 1M€ Cerrado

EUIN2017-87851 INTEGRACION DE OMICAS PARA LA TERAPIA DIRIGIDA EN INMUNOTERA... 10K€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

EXPAND IT EXPANDing Immune Cells and their Tumor Antigens during check... 3M€ Cerrado

CANCER-DC Dissecting Regulatory Networks That Mediate Dendritic Cell S... 2M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-03-27
Fecha Fin: 2028-03-31

Líder del proyecto

EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Lung cancer is the leading cause of cancer death. Immunotherapy improved survival rates, but efficacy is limited to selected patients. We recently discovered universal antigen presenting fibroblasts (apFibros) across human and murine lung tumors and showed that they directly stimulate cancer-specific CD4 T cells, creating immunological hot spots that support immune rejection. These studies achieved a breakthrough on the role of in situ cancer antigen presentation and proposed a novel model whereby tumors can sustain T cells independently of lymph nodes. Preliminary data suggest that lung apFibros help overcome resistance to checkpoint inhibitors. For their immunotherapeutic exploitation of apFibros two bottlenecks must be overcome: low numbers and incomplete understanding of their configurations. We will integrate computational and laboratory experiments and work in parallel in human and mouse models to generate perturbation datasets across single-cell/cell systems, transcriptomics/epigenomics, spatial/temporal levels, and dissect the molecular landscape that regulates fibroblast states. Our ultimate goal is to unravel perturbations that can diverge cancer-associated fibroblasts to antigen presenting states. The following questions are at the core of our proposal i) how do diverse fibroblast states emerge and evolve? ii) which gene regulatory networks drive specificity of these states? ii) which are the functional modules that are driven by apFibros and how are they mechanistically explained? iv) how can we transdifferentiate existing fibroblasts to acquire antigen presenting states? v) how can fibroblast reprogramming help overcome immunotherapy resistance? The proposed research should help advance mechanistic concepts in what we term the adaptive immune mesenchyme, decode the complexity of peripheral antigen presentation in tumors and beyond and promote targeting of the stroma for immunotherapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores